Skip to main content
. 2022 Sep 19;2022:7742760. doi: 10.1155/2022/7742760

Table 1.

The relationship between serum tumor marker levels and clinicopathological features in patients with IBD and rectal cancer (x¯±s).

Clinicopathological features n CA242 (U/ml) t P CA724 (U/ml) t P TPA (U/L) t P
Gender 0.738 0.463 0.607 0.546 1.206 0.233
 Male 36 16.20 ± 2.11 24.89 ± 2.14 162.95 ± 10.10
 Female 24 15.78 ± 2.23 24.55 ± 2.10 159.68 ± 10.58
Age (years old) 1.081 0.284 0.530 0.598 0.910 0.367
 ≥50 years old 34 16.23 ± 2.10 24.80 ± 2.13 161.55 ± 11.10
 <50 years old 26 15.64 ± 2.09 24.50 ± 2.23 158.78 ± 12.41
Tumor size (cm) 11.888 <0.001 0.786 0.435 0.577 0.566
 ≥5 32 18.44 ± 1.98 24.99 ± 2.10 161.25 ± 10.45
 <5 28 12.76 ± 1.68 24.56 ± 2.13 159.68 ± 10.58
Histological grades 3.146 0.012 6.223 0.012 2.653 0.023
 G1 15 13.10 ± 2.11 18.41 ± 2.23 149.23 ± 10.68
 G2 40 15.21 ± 2.13 24.55 ± 2.23 156.98 ± 12.14
 G3 5 17.42 ± 2.10 26.85 ± 2.14 169.79 ± 12.65
Growth modes 13.029 <0.001 5.157 0.040 2.660 0.096
 Ulcerative 30 14.23 ± 1.25 22.14 ± 2.65 156.21 ± 12.58
 Invasive 25 20.12 ± 1.10 26.98 ± 2.14 168.98 ± 12.65
 Contracted 5 11.10 ± 1.54 20.15 ± 2.10 149.65 ± 11.65
T stages 3.532 0.001 10.081 <0.001 4.392 <0.001
T1−2 20 14.26 ± 1.25 22.10 ± 2.12 155.26 ± 11.54
T3−4 40 15.65 ± 1.52 28.14 ± 2.22 169.23 ± 11.65
N stages 0.783 0.437 8.461 <0.001 0.955 0.344
N0 32 5.89 ± 1.23 10.63 ± 2.11 159.65 ± 12.10
N1−2 28 15.68 ± 1.44 21.95 ± 2.13 162.58 ± 11.58
M stages 1.208 0.232 8.866 <0.001 3.048 0.004
M0 52 15.55 ± 1.23 21.23 ± 2.20 154.98 ± 12.50
M1 8 16.23 ± 2.68 28.65 ± 2.23 169.21 ± 10.65
TNM stages 3.901 <0.001 9.669 <0.001 <0.001
 I-II 30 14.59 ± 1.26 22.65 ± 2.14 153.65 ± 12.10
 III-IV 30 16.68 ± 2.65 27.98 ± 2.13 166.54 ± 11.58
Perineural invasion 0.153 0.879 0.687 0.495 0.601 0.550
Y 5 15.85 ± 2.12 24.30 ± 2.12 158.65 ± 12.65
N 55 16.00 ± 2.10 24.98 ± 2.12 162.20 ± 12.65
Vascular invasion 0.287 0.775 1.426 0.159 0.477 0.656
Y 6 15.75 ± 2.16 24.23 ± 1.59 159.65 ± 13.26
N 54 16.01 ± 2.10 24.99 ± 1.20 162.20 ± 13.25